Role of endogenous platelet‐activating factor (PAF) in endotoxin‐induced portal hypertension in rats
S. Kitagawa,Y. Kubota,T. Yamaguchi,K. Fujimura,T. Binnaka,K. Tani,M. Ogura,T. Mizuno,K. Inoue
DOI: https://doi.org/10.1111/j.1440-1746.1992.tb01024.x
1992-10-01
Journal of Gastroenterology and Hepatology
Abstract:To determine the role of platelet‐activating factor (PAF) in endotoxin‐induced portal hypertension, we performed continuous recording of both blood pressure (BP) and portal venous pressure (PVP) in rats following the administration of intravenous PAF (25 ng/kg), intraportal PAF (25 ng/kg), intraportal endotoxin (2 mg/kg), and intraportal endotoxin (2 mg/kg) for 1 min subsequent to pretreatment with a specific PAF‐antagonist (CV‐6209, 1 mg/kg, i.v.). Basal resting values of both BP (102.3 ± 9.3 mmHg) and PVP (7.7 ± 1.2 mmHg) fell rapidly after intravenous infusion of PAF (BP: 36.7 ± 5.8 mmHg; PVP: 5.7 ± 0.8 mmHg) and followed by gradual return. Intraportal PAF infusion elicited a rapid but less severe depression of BP (57.2 ± 9.4 mmHg) as compared with intravenous PAF infusion, whereas PVP was increased transiently around 4 min after treatment (11.0 ± 5.3 mmHg). A similar degree of PVP elevation (10.7 ± 2.0 mmHg) was observed between 8 and 20 min after intraportal administration of endotoxin. Depression of BP was initiated 12 min after endotoxin administration but was not severe (76.6 ± 12.8 mmHg). CV‐6209 significantly alleviated the endotoxin‐induced elevation of PVP and completely inhibited the hypotension. These observations suggest that: (i) PAF‐induced elevation of PVP is a direct response of the liver to PAF; and (ii) endogenous PAF plays an important role in the endotoxin‐induced portal hypertension.